OBJECTIVE: Antipsychotic drugs are the mainstay of treatment for schizophrenia. However, a substantial proportion of patients are poorly responsive or resistant to first-line treatments, and clozapine treatment is often indicated. Therefore, we and others have used clozapine treatment as a proxy phenotype for antipsychotic treatment resistance in pharmacogenetic studies. In the present study, we utilized this phenotype to test previously-identified candidate genes for antipsychotic treatment response. METHOD: We assessed 89 Caucasian schizophrenia patients clinically assigned to clozapine treatment versus 190 Caucasian patients that were not selected for clozapine treatment. We conducted gene-based association tests on a set of 74 relevant candidate genes nominated in the CATIE pharmacogenetic study (Need et al., 2009), using the GATES procedure (Li et al., 2011). RESULTS: After correcting for multiple testing in the gene-based association test, the gene for brain derived neurotrophic factor (BDNF) was significantly associated with treatment resistance. The top single nucleotide polymorphisms (SNPs) in BDNF included rs11030104 (OR = 2.57), rs10501087 (OR = 2.19) and rs6265 (Val66Met) (OR = 2.08). These SNPs appear to be in high linkage disequilibrium with each other. CONCLUSION: BDNF appears to have a strong association with antipsychotic treatment resistance. Future studies are needed to replicate this finding and further elucidate the biological pathways underlying the association between BDNF and antipsychotic drug response.
OBJECTIVE: Antipsychotic drugs are the mainstay of treatment for schizophrenia. However, a substantial proportion of patients are poorly responsive or resistant to first-line treatments, and clozapine treatment is often indicated. Therefore, we and others have used clozapine treatment as a proxy phenotype for antipsychotic treatment resistance in pharmacogenetic studies. In the present study, we utilized this phenotype to test previously-identified candidate genes for antipsychotic treatment response. METHOD: We assessed 89 Caucasian schizophreniapatients clinically assigned to clozapine treatment versus 190 Caucasian patients that were not selected for clozapine treatment. We conducted gene-based association tests on a set of 74 relevant candidate genes nominated in the CATIE pharmacogenetic study (Need et al., 2009), using the GATES procedure (Li et al., 2011). RESULTS: After correcting for multiple testing in the gene-based association test, the gene for brain derived neurotrophic factor (BDNF) was significantly associated with treatment resistance. The top single nucleotide polymorphisms (SNPs) in BDNF included rs11030104 (OR = 2.57), rs10501087 (OR = 2.19) and rs6265 (Val66Met) (OR = 2.08). These SNPs appear to be in high linkage disequilibrium with each other. CONCLUSION:BDNF appears to have a strong association with antipsychotic treatment resistance. Future studies are needed to replicate this finding and further elucidate the biological pathways underlying the association between BDNF and antipsychotic drug response.
Authors: Takefumi Suzuki; Gary Remington; Benoit H Mulsant; Tarek K Rajji; Hiroyuki Uchida; Ariel Graff-Guerrero; David C Mamo Journal: Schizophr Res Date: 2011-10-14 Impact factor: 4.939
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: P R Szeszko; R Lipsky; C Mentschel; D Robinson; H Gunduz-Bruce; S Sevy; M Ashtari; B Napolitano; R M Bilder; J M Kane; D Goldman; A K Malhotra Journal: Mol Psychiatry Date: 2005-07 Impact factor: 15.992
Authors: T Lencz; T V Morgan; M Athanasiou; B Dain; C R Reed; J M Kane; R Kucherlapati; A K Malhotra Journal: Mol Psychiatry Date: 2007-03-20 Impact factor: 15.992
Authors: Joseph P McEvoy; Jeffrey A Lieberman; T Scott Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin S Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne Severe; John K Hsiao Journal: Am J Psychiatry Date: 2006-04 Impact factor: 19.242
Authors: Douglas M Ruderfer; Alexander W Charney; Ben Readhead; Brian A Kidd; Anna K Kähler; Paul J Kenny; Michael J Keiser; Jennifer L Moran; Christina M Hultman; Stuart A Scott; Patrick F Sullivan; Shaun M Purcell; Joel T Dudley; Pamela Sklar Journal: Lancet Psychiatry Date: 2016-02-23 Impact factor: 27.083
Authors: Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati Journal: Innov Clin Neurosci Date: 2015 Mar-Apr
Authors: Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll Journal: Schizophr Res Date: 2014-01-07 Impact factor: 4.939
Authors: Cathy K Wang; Michael S Xu; Colin J Ross; Ryan Lo; Ric M Procyshyn; Fidel Vila-Rodriguez; Randall F White; William G Honer; Alasdair M Barr Journal: Int J Methods Psychiatr Res Date: 2015-06-29 Impact factor: 4.035
Authors: J I Schweiger; E Bilek; A Schäfer; U Braun; C Moessnang; A Harneit; P Post; K Otto; N Romanczuk-Seiferth; S Erk; C Wackerhagen; M Mattheisen; T W Mühleisen; S Cichon; M M Nöthen; J Frank; S H Witt; M Rietschel; A Heinz; H Walter; A Meyer-Lindenberg; H Tost Journal: Neuropsychopharmacology Date: 2018-10-25 Impact factor: 7.853